Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet (PODD – Research Report), with a price target ...

Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

Right now, ResMed is sporting a Zacks Rank of #2 (Buy), while Insulet has a Zacks Rank of #3 (Hold). This means that RMD's earnings estimate revision activity has been more impressive, so investors ...

Insulet Corporation’s PODD rapid progress with its strategic imperatives on Omnipod platform is poised to help it grow in the upcoming quarters. The largely untapped diabetes market also ...